Letters in Drug Design & Discovery

G. Perry
University of Texas
San Antonio, TX
USA
Email: lddd@benthamscience.org

Back

Doxsaliform: A Novel N-Mannich Base Prodrug of a Doxorubicin Formaldehyde Conjugate

Author(s): P. S. Cogan, C. R. Fowler, G. C. Post, T. H. Koch.

Abstract:

Development of a water-soluble prodrug of doxorubicin-formaldehyde conjugate, a labile, active metabolite of doxorubicin, is described. The lead compound is the doxorubicin-salicylamide N-Mannich base, N-(2-hydroxybenzamidomethyl)-doxorubicin (doxsaliform), prepared in 72% yield from reaction of salicylamide with doxorubicin in the presence of formaldehyde. Doxsaliform releases doxorubicin-formaldehyde conjugate under physiological conditions with a half-life of 57 min. The stability of the prodrug is augmented both by salt formation in acidic media and by covalent modification of the 2-hydroxyl of the salicylamide moiety. Doxsaliform is 4 fold more active than doxorubicin against MCF-7 breast and PC-3 prostate cancer cell lines and 10 fold more active against the doxorubicin resistant MCF-7 / ADR cell line.

Keywords: doxorubicin, formaldehyde, prodrug, salicylamide, trigger

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 1
ISSUE: 3
Year: 2004
Page: [247 - 255]
Pages: 9
DOI: 10.2174/1570180043399000
Price: $58